No preservative in Zioptan (tafluprost) glaucoma drug from Merck may be a distinct advantage

sailboat  Tafluprost (Zioptan) was approved by the FDA to help lower increased eye pressure in people suffering from open-angle glaucoma. Importantly, the drug is also approved for people with abnormally high eye pressure (what your doctor would call ocular hypertension) which is a crucial risk factor for glaucoma. It has been pointed out by many experts (myself included), that the pills, medicine and in this case, drops don’t do you any good if they stay in the bottle.

An important point that has been missed in many outlets that simply reported the FDA approval of Zioptan is that there is a growing body of evidence saying it’s the preservatives that sting—. Increased eye pressure and certainly glaucoma requires ongoing treatment. Zioptan only requires once a day treatment in the evening which should be welcomed by consumers—yet the important thing—adherence or taking the medicine over time begs to be researched.

It appears that Zioptan as the first PRESERVATIVE FREE prostaglandin analog may have a huge advantage in patient tolerability and willingness of patients to continue treatment. The challenge to the ophthalmology community is to undertake the studies and report the expected findings!

Approval Date: 
Tue, 02/14/2012

This website is not intended as medical advice, and you should consult your doctor before changing or adding any medicines or vitamins to those you may now be taking and about applying any strategies BEFORE you adopt any approach in this report. While diligent care has been taken to ensure the accuracy of the information provided during the preparation of this edition, no claim is made that all known actions, uses or side effects, strategies for cost containment, targets or cholesterol pathways are included in this report. The accuracy and currentness of information are ever subject to change relative to new guidelines, new information derived from drug research, development and general usage.